A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population. In a real-world setting of new and ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
A clinical trial using genetic testing to match acute myeloid leukemia (AML) patients with new therapies is now open at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer ...
Wilmington, Delaware, United States, March 15, 2023 (GLOBE NEWSWIRE) -- According to the latest market research study by Transparency Market Research, “The global acute myeloid leukemia (AML) ...
Guidelines by the National Comprehensive Cancer Network (NCCN) recommend testing for seven known genetic changes in patients with Acute Myeloid Leukemia (AML). A study presented today at the American ...
Creating a synthetic control arm from previous clinical trials: Application to establishing early end points as indicators of overall survival in acute myeloid leukemia (AML). This is an ASCO Meeting ...
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. SAS® Transaction Monitoring Optimization includes advanced visualization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback